Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function

NCT ID: NCT00418119

Last Updated: 2007-01-04

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2008-01-31

Brief Summary

Erythropoietin Treatment in Patients with systolic left ventricular dysfunction, mild anemia and normal renal function

Conditions

Heart Failure

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

erythropoietin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Ischemic heart disease
• Systolic lv dysfunction
• Mild anemia
• Normal renal function
• Stable condition

Exclusion Criteria

• Pregnancy
• Unstable condition
• Under 18 years old

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rabin Medical Center

OTHER

Sponsor Role: lead

Principal Investigators

Tuvia Ben Gal, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiology Department Rabin medical Center

Ofer Shpilberg, Prof.

Role: STUDY_DIRECTOR

Hematology Department Rabin Medical Center

Daniel Murninkas, MD

Role: STUDY_DIRECTOR

Cardiology Department Rabin Medical Center

Locations

Cardiology Department, Rabin Medical Center

Petah Tikva, Petah Tikva, Israel

Countries

Israel

Central Contacts

Tuvia Ben Gal, MD

Role: CONTACT

bengalt@clalit.org.il

972-522757616

Daniel Murninkas, MD

Role: CONTACT

murninkasd@clalit.org.il

972-39376930

Facility Contacts

Tuvia Ben Gal, MD

Role: primary

bengalt@clalit.org.il

972-522757616

Daniel Murninkas, MD

Role: backup

murninkasd@clalit.org.il

972-39736930

Other Identifiers

4273

Identifier Type: -

Identifier Source: org_study_id